Skip to main content

Appraisals in progress

Patients, carers and patient organisations - please see our New medicines needing your views page for answers to some questions you might have about making a submission.

Clinical experts - please see our Clinical expert opinion for medicine appraisals page for background information.

We'd like to receive your submission before the stated deadline (so we can prepare the meeting papers). But we'll still try to include any that arrive late.

Medicine name: cannabidiol (Epidyolex®)

Reference number: 3201

Indication: Adjunctive therapy of seizures associated with tuberous sclerosis complex (TSC) for patients 2 years of age and older.

Patient and carer submission: Download form or submit online

Patient organisation submission: Download form or submit online

Clinical experts submission: Download form

Submission deadline: 21/09/2021

AWMSG meeting date: 08/12/2021

Medicine name: dabigatran etexilate (Pradaxa®)

Reference number: 2293

Indication: Treatment of VTE and prevention of recurrent VTE in paediatric patients from 8 years to less than 18 years of age.

Patient and carer submission: Download form or submit online

Patient organisation submission: Download form or submit online

Clinical experts submission: Download form

AWMSG meeting date: 08/12/2021

Medicine name: rivaroxaban (Xarelto®)

Reference number: 3875

Indication: Treatment of venous thromboembolism (VTE) and prevention of VTE recurrence in term neonates, infants and toddlers, children, and adolescents aged less than 18 years after at least 5 days of initial parenteral anticoagulation treatment.

Patient and carer submission: Download form or submit online

Patient organisation submission: Download form or submit online

Clinical experts submission: Download form

AWMSG meeting date: 08/12/2021

Medicine name: clostridium botulinum neurotoxin type A (Xeomin®)

Reference number: 3986

Indication: Symptomatic treatment in children and adolescents aged 2 to 17 years and weighing ≥ 12 kg of chronic sialorrhea due to neurological/neurodevelopmental disorders.

Patient and carer submission: Download form or submit online

Patient organisation submission: Download form or submit online

Clinical experts submission: Download form

AWMSG meeting date: 08/12/2021

Medicine name: tirbanibulin (Klisyri®)

Reference number: 4076

Indication: For the field treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis (Olsen grade 1) of the face or scalp in adults.

Patient and carer submission: Download form or submit online

Patient organisation submission: Download form or submit online

Clinical experts submission: Download form

Submission deadline: 29/11/2021

AWMSG meeting date: 09/02/2022

Medicine name: clostridium botulinum type A toxin-haemagglutinin complex (Dysport®)

Reference number: 2626

Indication: Symptomatic treatment of focal spasticity of upper limbs in paediatric cerebral palsy patients, two years of age or older.

Patient and carer submission: Download form or submit online

Patient organisation submission: Download form or submit online

Clinical experts submission: Download form

Submission deadline: 19/11/2021

AWMSG meeting date: 09/02/2022

Medicine name: inclisiran (Leqvio®)

Reference number: 3746

Indication: In adults with primary hypercholesterolaemia (heterozygous familial and non‑familial) or mixed dyslipidaemia, as an adjunct to diet: in combination with a statin or statin with other lipid‑lowering therapies in patients unable to reach LDL‑C goals with the maximum tolerated dose of a statin, or; alone or in combination with other lipid‑lowering therapies in patients who are statin‑intolerant, or for whom a statin is contraindicated.

Patient and carer submission: Download form or submit online

Patient organisation submission: Download form or submit online

Clinical experts submission: Download form

Submission deadline: 01/12/2021

AWMSG meeting date: 09/02/2022

Medicine name: buprenorphine (Sixmo®)

Reference number: 4262

Indication: Substitution treatment for opioid dependence in clinically stable adult patients who require no more than 8 mg/day of sublingual buprenorphine, within a framework of medical, social and psychological treatment.

Patient and carer submission: Download form or submit online

Patient organisation submission: Download form or submit online

Clinical experts submission: Download form

Submission deadline: 20/09/2021

AWMSG meeting date: 09/02/2021

Medicine name: ravulizumab (Ultomiris®)

Reference number: 4869

Indication: For the treatment of paediatric patients with a body weight of 10 kg or above with paroxysmal nocturnal haemoglobinuria (PNH)

Patient and carer submission: Download form or submit online

Patient organisation submission: Download form or submit online

Clinical experts submission: Download form

AWMSG meeting date: 09/02/2022

Medicine name: hydrocortisone MR (Efmody®)

Reference number: 3017

Indication: Treatment of congenital adrenal hyperplasia (CAH) in adolescents aged 12 years and over and adults.

Patient and carer submission: Download form or submit online

Patient organisation submission: Download form or submit online

Clinical experts submission: Download form

Submission deadline: TBC

AWMSG meeting date: 09/03/2022

Medicine name: mercaptamine bitartrate (Procysbi®)

Reference number: 4804

Indication: Treatment of proven nephropathic cystinosis. Mercaptamine reduces cystine accumulation in some cells (e.g. leukocytes, muscle and liver cells) of nephropathic cystinosis patients and, when treatment is started early, it delays the development of renal failure.

Patient and carer submission: Download form or submit online

Patient organisation submission: Download form or submit online

Clinical experts submission: Download form

Submission deadline: 07/01/2022

AWMSG meeting date: 27/04/2022

Medicine name: oritavancin (Tenkasi®)

Reference number: 5023

Indication: Treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults.

Patient and carer submission: Download form or submit online

Patient organisation submission: Download form or submit online

Clinical experts submission: Download form

Submission deadline: 07/01/2022

AWMSG meeting date: 27/04/2022

Medicine name: ambrisentan (Volibris®)

Reference number: 4819

Indication: Treatment of PAH in adolescents and children (aged 8 to less than 18 years) of WHO Functional Class (FC) II to III including use in combination treatment. Efficacy has been shown in IPAH, familial, corrected congenital and in PAH associated with connective tissue disease.

Patient and carer submission: Download form or submit online

Patient organisation submission: Download form or submit online

Clinical experts submission: Download form

Submission deadline: TBC

AWMSG meeting date: TBC